156 related articles for article (PubMed ID: 14561437)
21. A double-blind placebo-controlled study of Org 3770 in depressed outpatients.
Claghorn JL; Lesem MD
J Affect Disord; 1995 Jun; 34(3):165-71. PubMed ID: 7560544
[TBL] [Abstract][Full Text] [Related]
22. Mirtazapine for treatment-resistant depression: a preliminary report.
Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data.
Kasper S
Int Clin Psychopharmacol; 1995 Dec; 10 Suppl 4():25-35. PubMed ID: 8930007
[TBL] [Abstract][Full Text] [Related]
24. Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients.
Schüle C; Baghai TC; di Michele F; Eser D; Pasini A; Romeo E; Rupprecht R
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):308-13. PubMed ID: 20218794
[TBL] [Abstract][Full Text] [Related]
25. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.
Schüle C; Baghai TC; Eser D; Zwanzger P; Jordan M; Buechs R; Rupprecht R
Psychopharmacology (Berl); 2006 Jul; 186(4):601-11. PubMed ID: 16758243
[TBL] [Abstract][Full Text] [Related]
26. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED
J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
28. Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action.
Horstmann S; Dose T; Lucae S; Kloiber S; Menke A; Hennings J; Spieler D; Uhr M; Holsboer F; Ising M
Psychoneuroendocrinology; 2009 Feb; 34(2):238-248. PubMed ID: 18926641
[TBL] [Abstract][Full Text] [Related]
29. Mirtazapine in major depression with comorbid generalized anxiety disorder.
Goodnick PJ; Puig A; DeVane CL; Freund BV
J Clin Psychiatry; 1999 Jul; 60(7):446-8. PubMed ID: 10453798
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression.
Kim SW; Shin IS; Kim JM; Kim YC; Kim KS; Kim KM; Yang SJ; Yoon JS
Psychiatry Clin Neurosci; 2008 Feb; 62(1):75-83. PubMed ID: 18289144
[TBL] [Abstract][Full Text] [Related]
31. Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium.
Moustgaard G
J Clin Psychopharmacol; 2000 Apr; 20(2):268. PubMed ID: 10770470
[No Abstract] [Full Text] [Related]
32. An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Ersoy MA; Noyan AM; Elbi H
Clin Drug Investig; 2008; 28(2):113-20. PubMed ID: 18211119
[TBL] [Abstract][Full Text] [Related]
33. Sertraline- and mirtazapine-induced severe neutropenia.
Ozcanli T; Unsalver B; Ozdemir S; Ozmen M
Am J Psychiatry; 2005 Jul; 162(7):1386. PubMed ID: 15994730
[No Abstract] [Full Text] [Related]
34. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression.
Kang RH; Hahn SW; Choi MJ; Lee MS
Neuropsychobiology; 2007; 56(1):1-5. PubMed ID: 17943025
[TBL] [Abstract][Full Text] [Related]
35. Re-administration of mirtazapine could overcome previous mirtazapine- associated restless legs syndrome?
Pae CU; Kim TS; Kim JJ; Chae JH; Lee CU; Lee SJ; Paik IH; Lee C
Psychiatry Clin Neurosci; 2004 Dec; 58(6):669-70. PubMed ID: 15601394
[No Abstract] [Full Text] [Related]
36. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder.
Chang HS; Lee HY; Cha JH; Won ES; Ham BJ; Kim B; Lee MS
J Clin Psychopharmacol; 2014 Aug; 34(4):446-54. PubMed ID: 24911443
[TBL] [Abstract][Full Text] [Related]
37. Treatment with mirtazapine and venlafaxine increases noradrenaline excretion in depressed patients.
Lecei O; Lederbogen F; Gronau W; Scharnholz B; Terhardt J; Schilling C; Gilles M; Kopf D; Roth HJ; Weber-Hamann B; Deuschle M
J Clin Psychopharmacol; 2012 Aug; 32(4):574-6. PubMed ID: 22760352
[No Abstract] [Full Text] [Related]
38. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice.
Grasmäder K; Verwohlt PL; Kühn KU; Frahnert C; Hiemke C; Dragicevic A; von Widdern O; Zobel A; Maier W; Rao ML
Pharmacopsychiatry; 2005 May; 38(3):113-7. PubMed ID: 15902580
[TBL] [Abstract][Full Text] [Related]
39. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction.
Koutouvidis N; Pratikakis M; Fotiadou A
Int Clin Psychopharmacol; 1999 Jul; 14(4):253-5. PubMed ID: 10468319
[TBL] [Abstract][Full Text] [Related]
40. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine.
Schmid DA; Wichniak A; Uhr M; Ising M; Brunner H; Held K; Weikel JC; Sonntag A; Steiger A
Neuropsychopharmacology; 2006 Apr; 31(4):832-44. PubMed ID: 16237393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
